Height and prostate cancer risk: A large nested case-control study (ProtecT) and meta-analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 9, 2008, Pages 2325-2336

  Zuccolo, Luisa ^a   Harris, Ross ^a   Gunnell, David ^b   Oliver, Steven ^a   Lane, Jane Athene ^a   Davis, Michael ^a   Donovan, Jenny ^a   Neal, David ^c   Hamdy, Freddie ^d   Beynon, Rebecca ^a   Savovic, Jelena ^a   Martin, Richard Michael ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BODY HEIGHT; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RISK; CLINICAL TRIAL; DATA BASE; DISEASE ASSOCIATION; GENERAL PRACTICE; HUMAN; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; SYSTEMATIC REVIEW; UNITED KINGDOM;

AGED; BODY HEIGHT; CASE-CONTROL STUDIES; DISEASE PROGRESSION; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 53349096955     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0342     Document Type: Article

References (93)

1. Tanner JM. Foetus into man: physical growth from conception to maturity. Ware (United Kingdom): Castlemead Publications; 1989.
2. Gunnell D. Can adult anthropometry be used as a 'biomarker' for prenatal and childhood exposures? Int J Epidemiol 2002;31:390-4.
3. Gunnell D, Okasha M, Smith GD, Oliver SE, Sandhu J, Holly JMP. Height, leg length, and cancer risk: a systematic review. Epidemiol Rev 2001;23:313-42.
4. Leitch I. Growth and health. Br J Nutr 1951;5:142-51.
5. Leary S, Smith GD, Ness A. Smoking during pregnancy and components of stature in offspring. Am J Hum Biol 2006;18:502-12.
6. Rogers I, Emmett P, Gunnell D, Dunger D, Holly J. Milk as a food for growth? The insulin-like growth factors link. Public Health Nutr 2006;9:359-68.
7. Gunnell DJ, Smith GD, Frankel SJ, Kemp M, Peters TJ. Socioeconomic and dietary influences on leg length and trunk length in childhood: a reanalysis of the Carnegie (Boyd Orr) survey of diet and health in prewar Britain (1937-39). Paediatr Perinat Epidemiol 1998;12 Suppl 1:96-113.
8. Wadsworth ME, Hardy RJ, Paul AA, Marshall SF, Cole TJ. Leg and trunk length at 43 years in relation to childhood health, diet and family circumstances; evidence from the 1946 national birth cohort. Int J Epidemiol 2002;31:383-90.
9. Chandler PJ, Bock RD. Age changes in adult stature: trend estimation from mixed longitudinal data. Ann Hum Biol 1991;18:433-40.
10. Rogers I, Metcalfe C, Gunnell D, Emmett P, Dunger D, Holly J. Insulin-like growth factor-I and growth in height, leg length, and trunk length between ages 5 and 10 years. J Clin Endocrinol Metabol 2006;91:2514-9.
11. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
12. Donovan J, Mills N, Smith M, et al. Quality improvement report: improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. BMJ 2002;325:766-70.
13. MacInnis R, English D. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006;17:989-1003.
14. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91:1017-24.
15. Kvale R, Auvinen A, Adami HO, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007;99:1881-7.
16. Ohori M, Wheeler TM, Scardino PT. The new American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Cancer 1994;73:104-14.
17. Gunnell D. Can adult anthropometry be used as a biomarker for prenatal and childhood exposures? Int J Epidemiol 2002;31:390-4.
18. American Institute for Cancer Research and World Cancer Research Fund. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington DC: AICR; 2007.
19. WCRF. Systematic literature review protocol. WCRF Web site 2008 January 23. Available from http://www.wcrf.org/research/research_pdfs/prostate_protocol. pdf.Accessed 2008 Jan 23.
20. Habel LA, Van Den Eeden SK, Friedman GD. Body size, age at shaving initiation, and prostate cancer in a large, multiracial cohort. Prostate 2000;43:136-43.
21. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001;10:345-53.
22. Hayes RB, Ziegler RG, Gridley G, et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 1999;8:25-34.
23. Whittemore AS, Kolonel LN, Wu AH, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada [see comment]. J 1995;87:652-61.
24. Albanes D, Jones DY, Schatzkin A, Micozzi MS, Taylor PR. Adult stature and risk of cancer. Cancer Res 1988;48:1658-62.
25. Andersson SO, Wolk A, Bergstrom R, et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J 1997;89:385-9.
26. Batty GD, Shipley MJ, Langenberg C, Marmot MG, Davey Smith G. Adult height in relation to mortality from 14 cancer sites in men in London (UK): evidence from the original Whitehall study. Ann Oncol 2006;17:157-66.
27. Cerhan JR, Torner JC, Lynch CF, et al. Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). Cancer Causes Control 1997;8:229-38.
28. Davey-Smith G, Hart C, Upton M, et al. Height and risk of death among men and women: aetiological implications of associations with cardiorespiratory disease and cancer mortality. J Epidemiol Community Health 2000;54:97-103.
29. Engeland A, Tretli S, Bjorge T. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer 2003;89:1237-42.
30. Freeman VL, Liao Y, Durazo-Arvizu R, Cooper RS. Height and risk of fatal prostate cancer: findings from the National Health Interview Survey (1986 to 1994). Ann Epidemiol 2001;11:22-7.
31. Greenwald P, Damon A, Kirmss V, Polan AK. Physical and demographic features of men before developing cancer of the prostate. J 1974;53:341-6.
32. Gunnell D, May M, Ben-Shlomo Y, Yarnell J, Smith GD. Height, leg length, and cancer: the Caerphilly Study. Nutr Cancer 2003;47:34-9.
33. Hebert PR, Ajani U, Cook NR, Lee IM, Chan KS, Hennekens CH. Adult height and incidence of cancer in male physicians (United States). Cancer Causes Control 1997;8:591-7.
34. Jonsson F, Wolk A, Pedersen NL, et al. Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish Twin Registry. Int J Cancer 2003;106:594-9.
35. Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S. Association of body mass index and height with risk of prostate cancer among middle-aged Japanese men. Br J Cancer 2006;94:740-2.
36. Lamharzi N, Johnson MM, Goodman G, et al. Polymorphic markers in the 5α-reductase type II gene and the incidence of prostate cancer. Int J Cancer 2003;105:480-3.
37. Le Marchand L, Kolonel LN, Wilkens LR, Myers BC, Hirohata T. Animal fat consumption and prostate cancer: a prospective study in Hawaii [see comment]. Epidemiology 1994;5:276-82.
38. Littman AJ, White E, Kristal AR. Anthropometrics and prostate cancer risk. Am J Epidemiol 2007;165:1271-9.
39. Lund HL, Wisloff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006;164:769-74.
40. MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG. Body Size and composition and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2003;12:1417-21.
41. Nilsen TI, Vatten LJ. Anthropometry and prostate cancer risk: a prospective study of 22,248 Norwegian men. Cancer Causes Control 1999;10:269-75.
42. Platz EA, De Marzo AM, Erlinger TP, et al. No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. Prostate 2004;59:393-400.
43. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004;15:255-65.
44. Putnam SD, Cerhan JR, Parker AS, et al. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol 2000;10:361-9.
45. Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA. Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study [see comment]. Am J Epidemiol 2000;151:541-9.
46. Sequoia JSP, Wright ME, McCarron P, et al. A Prospective Investigation of Height and Prostate Cancer Risk. Cancer Epidemiol Biomarkers Prev 2006;15:2174-8.
47. Stattin P, Bylund A, Biessy C, Kaaks R, Hallmans G, Adlercreutz H. Prospective study of plasma enterolactone and prostate cancer risk (Sweden). Cancer Causes Control 2004;15:1095-102.
48. Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev 1997;6:863-73.
49. Andersson SO, Baron J, Wolk A, Lindgren C, Bergstrom R, Adami HO. Early life risk factors for prostate cancer: a population-based case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 1995;4:187-92.
50. Dal ML, Zucchetto A, la VC, et al. Prostate cancer and body size at different ages: an Italian multicentre case-control study. Br J Cancer 2004;90:2176-80.
51. Demark-Wahnefried W, Conaway MR, Robertson CN, Mathias BJ, Anderson EE, Paulson DF. Anthropometric risk factors for prostate cancer. Nutr Cancer 1997;28:302-7.
52. Fincham SM, Hill GB, Hanson J, Wijayasinghe C. Epidemiology of prostatic cancer: a case-control study. Prostate 1990;17:189-206.
53. Friedenreich CM, McGregor SE, Courneya KS, Angyalfi SJ, Elliott FG. Case-control study of anthropometric measures and prostate cancer risk. Int J Cancer 2004;110:278-83.
54. Furuya Y, Akimoto S, Akakura K, Ito H. Smoking and obesity in relation to the etiology and disease progression of prostate cancer in Japan. Int J Urol 1998;5:134-7.
55. Giles GG, Severi G, English DR, et al. Early growth, adult body size and prostate cancer risk. Int J Cancer 2003;103:241-5.
56. Hayes RB, de Jong FH, Raatgever J, et al. Physical characteristics and factors related to sexual development and behaviour and the risk for prostatic cancer. Eur J Cancer Prev 1992;1:239-45.
57. Hill P, Wynder EL, Garbaczewski L, Walker AR. Effect of diet on plasma and urinary hormones in South African black men with prostatic cancer. Cancer Res 1982;42:3864-9.
58. Hsieh CC, Thanos A, Mitropoulos D, Deliveliotis C, Mantzoros CS, Trichopoulos D. Risk factors for prostate cancer: a case-control study in Greece. Int J Cancer 1999;80:699-703.
59. Hsing AW, Deng J, Sesterhenn IA, et al. Body size and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2000;9:1335-41.
60. Huang SP, Chou YH, Chang WS, et al. Androgen receptor gene polymorphism and prostate cancer in Taiwan. J Formos Med Assoc 2003;102:680-6.
61. John EM, Schwartz GG, Koo J, Van Den BD, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 2005;65:5470-9.
62. Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT. A case-control study of diet and prostate cancer. Br J Cancer 1997;76:678-87.
63. Kolonel LN, Yoshizawa CN, Hankin JH. Diet and prostatic cancer: a case-control study in Hawaii. Am J Epidemiol 1988;127:999-1012.
64. Koppel M, Meranze DR, Shimkin MB. Characteristics of patients with prostatic carcinoma: a control case study on 83 autopsy pairs. J Urol 1967;98:229-33.
65. La Vecchia C, Negri E, Parazzini F, et al. Height and cancer risk in a network of case-control studies from Northern Italy. Int J Cancer 1990;45:275-9.
66. Lightfoot N, Conlon M, Kreiger N, Sass-Kortsak A, Purdham J, Darlington G. Medical history, sexual, and maturational factors and prostate cancer risk. Ann Epidemiol 2004;14:655-62.
67. Liu X, Rybicki BA, Casey G, Witte JS. Relationship between body size and prostate cancer in a sibling based case-control study. J Urol 2005;174:2169-73.
68. Norrish AE, McRae CU, Holdaway IM, Jackson RT. Height-related risk factors for prostate cancer. Br J Cancer 2000;82:241-5.
69. Porter MP, Stanford JL. Obesity and the risk of prostate cancer. Prostate 2005;62:316-21.
70. Rao AV, Fleshner N, Garwal S. Serum and tissue lycopene and biomarkers of oxidation in prostate cancer patients: a case-control study. Nutr Cancer 1999;33:159-64.
71. Villeneuve PJ, Johnson KC, Kreiger N, Mao Y; The Canadian Cancer Registries Epidemiology Research Group. Risk factors for prostate cancer: results from the Canadian National Enhanced Cancer Surveillance System. Cancer Causes Control 1999;10:355-67.
72. Walker AR, Walker BF, Tsotetsi NG, Sebitso C, Siwedi D, Walker AJ. Case-control study of prostate cancer in black patients in Soweto, South Africa. Br J Cancer 1992;65:438-41.
73. Wynder EL, Mabuchi K, Whitmore WF, Jr. Epidemiology of cancer of the prostate. Cancer 1971;28:344-60.
74. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1997;6:557-63.
75. Thune I, Lund E. Physical activity and the risk of prostate and testicular cancer: a cohort study of 53,000 Norwegian men. Cancer Causes Control 1994;5:549-56.
76. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007;121:1571-8.
77. Fowke JH, Signorello LB, Chang SS, et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer 2006;107:2361-7.
78. Werny DM, Thompson T, Saraiya M, et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev 2007;16:70-6.
79. Fowke JH, Motley SS, Cookson MS, et al. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis 2006;10:137-42.
80. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
81. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
82. Batty GD, Leon DA. Socio-economic position and coronary heart disease risk factors in children and young people: evidence from UK epidemiological studies. Eur J Public Health 2002;12:263-72.
83. Spencer BA, Babey SH, Etzioni DA, et al. A population-based survey of prostate-specific antigen testing among California men at higher risk for prostate carcinoma. Cancer 2006;106:765-74.
84. Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 2007;29:88-97.
85. Oliver SE. PhD Thesis. Department of Social Medicine, University of Bristol; 2002.
86. Gunnell D, Berney L, Holland P, et al. How accurately are height, weight and leg length reported by the elderly, and how closely are they related to measurements recorded in childhood? Int J Epidemiol 2000;29:456-64.
87. Spencer EA, Appleby PN, Davey GK, Key TJ. Validity of self-reported height and weight in 4808 EPIC-Oxford participants. Public Health Nutr 2002;5:561-5.
88. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Height loss in older men: associations with total mortality and incidence of cardiovascular disease. Arch Intern Med 2006;166:2546-52.
89. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor I and prostate cancer risk: A prospective study. Science 1998;279:563-6.
90. Vatten LJ, Kvinnsland S. Body height and risk of breast cancer. A prospective study of 23,831 Norwegian women. Br J Cancer 1990;61:881-5.
91. Ben-Shlomo Y, Holly J, McCarthy A, Savage P, Davies D, Davey Smith G. Pre and post natal milk supplementation and adult insulin-like growth factor I: long term follow-up of a randomised controlled trial. Cancer Epidemiol Biomarkers Prev 2005;14:1336-9.
92. Chyou PH, Nomura AM, Stemmermann GN. A prospective study of weight, body mass index and other anthropometric measurements in relation to site-specific cancers. Int J Cancer 1994;57:313-7.
93. Veierod MB, Laake P, Thelle DS. Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. Int J Cancer 1997;73:634-8.